22-oxacalcitriol	22-oxacalcitriol	O	O	OTHERS	I
suppresses	suppresses	O	O	O	O
secondary	secondary	O	O	OTHERS	I
hyperparathyroidism	hyperparathyroidism	O	O	OTHERS	I
without	without	O	O	O	O
inducing	inducing	O	O	O	O
low	low	O	O	OTHERS	I
bone	bone	O	O	OTHERS	I
turnover	turnover	O	O	OTHERS	I
in	in	O	O	O	O
dogs	dogs	O	O	O	O
with	with	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Calcitriol	calcitriol	O	O	OTHERS	I
therapy	therapy	O	O	O	O
suppresses	suppresses	O	O	O	O
serum	serum	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
parathyroid	parathyroid	CHEMICALS	O	OTHERS	I
hormone	hormone	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
PTH	pth	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
but	but	O	O	O	O
has	has	O	O	O	O
several	several	O	O	O	O
drawbacks	drawbacks	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
and/or	and/or	O	O	O	O
marked	marked	O	O	O	O
suppression	suppression	O	O	OTHERS	I
of	of	O	O	OTHERS	I
bone	bone	O	O	OTHERS	I
turnover	turnover	O	O	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
may	may	O	O	O	O
lead	lead	O	O	OTHERS	I
to	to	O	O	O	O
adynamic	adynamic	O	O	OTHERS	I
bone	bone	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
new	new	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
D	d	CHEMICALS	O	OTHERS	I
analogue	analogue	O	O	O	O
,	,	O	O	O	O
22-oxacalcitriol	22-oxacalcitriol	O	O	OTHERS	I
(	(	O	O	O	O
OCT	oct	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
shown	shown	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
promising	promising	O	O	O	O
characteristics	characteristics	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
undertaken	undertaken	O	O	O	O
to	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
OCT	oct	O	O	OTHERS	I
on	on	O	O	O	O
serum	serum	O	O	O	O
PTH	pth	O	O	O	O
levels	levels	O	O	O	O
and	and	O	O	O	O
bone	bone	O	O	O	O
turnover	turnover	O	O	O	O
in	in	O	O	O	O
states	states	O	O	O	O
of	of	O	O	O	O
normal	normal	O	O	O	O
or	or	O	O	O	O
impaired	impaired	O	O	OTHERS	I
renal	renal	O	O	OTHERS	I
function	function	O	O	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Sixty	sixty	O	O	O	O
dogs	dogs	O	O	O	O
were	were	O	O	O	O
either	either	O	O	O	O
nephrectomized	nephrectomized	O	O	O	O
(	(	O	O	O	O
Nx	nx	O	O	O	O
,	,	O	O	O	O
N	n	O	O	OTHERS	I
=	=	O	O	O	O
38	38	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
sham-operated	sham-operated	O	O	O	O
(	(	O	O	O	O
Sham	sham	O	O	O	O
,	,	O	O	O	O
N	n	O	O	OTHERS	I
=	=	O	O	O	O
22	22	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
animals	animals	O	O	O	O
received	received	O	O	O	O
supplemental	supplemental	O	O	O	O
phosphate	phosphate	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
enhance	enhance	O	O	O	O
PTH	pth	O	O	O	O
secretion	secretion	O	O	O	O
.	.	O	O	O	O

Fourteen	fourteen	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
start	start	O	O	O	O
of	of	O	O	O	O
phosphate	phosphate	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
,	,	O	O	O	O
half	half	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
Nx	nx	O	O	O	O
and	and	O	O	O	O
Sham	sham	O	O	O	O
dogs	dogs	O	O	O	O
received	received	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
OCT	oct	O	O	OTHERS	I
(	(	O	O	O	O
three	three	O	O	O	O
times	times	O	O	O	O
per	per	O	O	O	O
week	week	O	O	O	O
)	)	O	O	O	O
;	;	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
half	half	O	O	O	O
were	were	O	O	O	O
given	given	O	O	O	O
vehicle	vehicle	O	O	O	O
for	for	O	O	O	O
60	60	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

Thereafter	thereafter	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
modalities	modalities	O	O	O	O
for	for	O	O	O	O
a	a	O	O	O	O
subset	subset	O	O	O	O
of	of	O	O	O	O
animals	animals	O	O	O	O
were	were	O	O	O	O
crossed	crossed	O	O	O	O
over	over	O	O	O	O
for	for	O	O	O	O
an	an	O	O	O	O
additional	additional	O	O	O	O
eight	eight	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

Biochemical	biochemical	O	O	O	O
and	and	O	O	O	O
hormonal	hormonal	O	O	O	O
indices	indices	O	O	O	O
of	of	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
bone	bone	O	O	O	O
metabolism	metabolism	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
throughout	throughout	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
bone	bone	O	O	O	O
biopsies	biopsies	O	O	O	O
were	were	O	O	O	O
done	done	O	O	O	O
at	at	O	O	O	O
baseline	baseline	O	O	O	O
,	,	O	O	O	O
60	60	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
OCT	oct	O	O	OTHERS	I
or	or	O	O	O	O
vehicle	vehicle	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
crossover	crossover	O	O	O	O
period	period	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
Nx	nx	O	O	O	O
dogs	dogs	O	O	O	O
,	,	O	O	O	O
OCT	oct	O	O	OTHERS	I
significantly	significantly	O	O	O	O
decreased	decreased	O	O	O	O
serum	serum	O	O	O	O
PTH	pth	O	O	O	O
levels	levels	O	O	O	O
soon	soon	O	O	O	O
after	after	O	O	O	O
the	the	O	O	O	O
induction	induction	O	O	O	O
of	of	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
insufficiency	insufficiency	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
long-standing	long-standing	O	O	O	O
secondary	secondary	O	O	OTHERS	I
hyperparathyroidism	hyperparathyroidism	O	O	OTHERS	I
,	,	O	O	O	O
OCT	oct	O	O	OTHERS	I
(	(	O	O	O	O
0.03	0.03	O	O	O	O
microg/kg	microg/kg	O	O	O	O
)	)	O	O	O	O
stabilized	stabilized	O	O	O	O
serum	serum	O	O	O	O
PTH	pth	O	O	O	O
levels	levels	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

Serum	serum	O	O	O	O
PTH	pth	O	O	O	O
levels	levels	O	O	O	O
rose	rose	O	O	O	O
thereafter	thereafter	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
the	the	O	O	O	O
rise	rise	O	O	O	O
was	was	O	O	O	O
less	less	O	O	O	O
pronounced	pronounced	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
baseline	baseline	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
rise	rise	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
Nx	nx	O	O	O	O
control	control	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
accompanied	accompanied	O	O	O	O
by	by	O	O	O	O
episodes	episodes	O	O	O	O
of	of	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
hyperphosphatemia	hyperphosphatemia	O	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
animals	animals	O	O	O	O
with	with	O	O	O	O
normal	normal	O	O	O	O
renal	renal	O	O	O	O
function	function	O	O	O	O
,	,	O	O	O	O
OCT	oct	O	O	OTHERS	I
induced	induced	O	O	O	O
a	a	O	O	O	O
transient	transient	O	O	O	O
decrease	decrease	O	O	O	O
in	in	O	O	O	O
serum	serum	O	O	O	O
PTH	pth	O	O	O	O
levels	levels	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
0.1	0.1	O	O	O	O
microg/kg	microg/kg	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
sustained	sustained	O	O	O	O
with	with	O	O	O	O
lowering	lowering	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
doses	doses	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
Nx	nx	O	O	O	O
dogs	dogs	O	O	O	O
,	,	O	O	O	O
OCT	oct	O	O	OTHERS	I
reversed	reversed	O	O	O	O
abnormal	abnormal	O	O	O	O
bone	bone	O	O	O	O
formation	formation	O	O	O	O
,	,	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
woven	woven	O	O	OTHERS	I
osteoid	osteoid	O	O	OTHERS	I
and	and	O	O	O	O
fibrosis	fibrosis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
significantly	significantly	O	O	O	O
alter	alter	O	O	O	O
the	the	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
bone	bone	O	O	O	O
turnover	turnover	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
addition	addition	O	O	O	O
,	,	O	O	O	O
OCT	oct	O	O	OTHERS	I
improved	improved	O	O	O	O
mineralization	mineralization	O	O	O	O
lag	lag	O	O	O	O
time	time	O	O	O	O
,	,	O	O	O	O
(	(	O	O	O	O
that	that	O	O	O	O
is	is	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
rate	rate	O	O	O	O
at	at	O	O	O	O
which	which	O	O	O	O
osteoid	osteoid	O	O	O	O
mineralizes	mineralizes	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
both	both	O	O	O	O
Nx	nx	O	O	O	O
and	and	O	O	O	O
Sham	sham	O	O	O	O
dogs	dogs	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
These	these	O	O	O	O
results	results	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
even	even	O	O	O	O
though	though	O	O	O	O
OCT	oct	O	O	OTHERS	I
does	does	O	O	O	O
not	not	O	O	O	O
completely	completely	O	O	O	O
prevent	prevent	O	O	O	O
the	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
hypercalcemia	hypercalcemia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
experimental	experimental	O	O	O	O
dogs	dogs	O	O	O	O
with	with	O	O	O	O
renal	renal	O	DISEASE	OTHERS	I
insufficiency	insufficiency	O	DISEASE	OTHERS	I
,	,	O	O	O	O
it	it	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
of	of	O	O	O	O
use	use	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
secondary	secondary	O	O	OTHERS	I
hyperparathyroidism	hyperparathyroidism	O	O	OTHERS	I
because	because	O	O	O	O
it	it	O	O	O	O
does	does	O	O	O	O
not	not	O	O	O	O
induce	induce	O	O	O	O
low	low	O	O	OTHERS	I
bone	bone	O	O	OTHERS	I
turnover	turnover	O	O	OTHERS	I
and	and	O	O	O	O
,	,	O	O	O	O
therefore	therefore	O	O	O	O
,	,	O	O	O	O
does	does	O	O	O	O
not	not	O	O	O	O
increase	increase	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
adynamic	adynamic	O	O	OTHERS	I
bone	bone	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

